FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2534353580> ?p ?o ?g. }

• W2534353580 endingPage "3485" @default.
• W2534353580 startingPage "3485" @default.
• W2534353580 abstract "Abstract Abstract 3485 Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in the treatment of several B cell malignancies. Bruton's tyrosine kinase (Btk) plays a key role in promoting B cell proliferation and survival through participation in the BCR signaling pathway and represents a promising new drug target. AVL-292 is a covalent, highly selective, orally active small molecule inhibitor of Btk currently being evaluated in a Phase 1b clinical trial in relapsed, refractory B cell malignancies including Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin lymphomas. AVL-292 forms a covalent bond with Cys481 in Btk and potently inhibits Btk in biochemical (IC50 < 0.5nM) and cellular assays (EC50 1–10 nM) including anti-IgM stimulation of BCR signaling, B cell proliferation and activation. A quantitative pharmacodynamic assay to determine the level of AVL-292 bonded to Btk in vitro or in vivo was developed and this drug-target engagement by AVL-292 was shown to correlate directly with inhibition of Btk enzyme activity and substrate phosphorylation. To rationally determine the dose and dose frequency of AVL-292 most likely to benefit patients and to reduce the potential for sub-therapeutic dosing in initial oncology patient cohorts, AVL-292 was administered to healthy adult subjects in a double-blind, placebo controlled, single ascending dose study. This study assessed safety, pharmacokinetics, and quantitatively measured Btk protein levels and AVL-292-Btk engagement in freshly isolated peripheral B lymphocytes. In healthy human subjects, AVL-292 was found to be safe and well tolerated following oral administration at dose levels ranging from 0.5–7.0 mg/kg. AVL-292 plasma levels and pharmacodynamic measurement of Btk engagement was dose-proportional across cohorts. All subjects that received 1.0 mg/kg AVL-292 achieved >80% Btk engagement and mean peak plasma levels (Cmax 365 ng/mL) of AVL-292 were rapidly achieved (Tmax median 40 min). Subjects receiving 2.0 mg/kg AVL-292 had a mean peak plasma concentration of 542 ng/mL. All subjects demonstrated >84% Btk engagement at this dose, with 5 of 6 subjects achieving >98% drug-target engagement. Although AVL-292 plasma levels declined substantially by 8 hours, Btk engagement persisted throughout 24 hours, demonstrating that covalent inhibition of Btk with AVL-292 enables prolonged duration of activity without high levels of circulating drug. These results suggest that a once daily dosing schedule is sufficient for sustained Btk inhibition. Furthermore, the Btk protein level in circulating B lymphocytes from all study subjects was evaluated and the mean level was found to be 417.7 pg Btk/mg total protein. Interestingly, this finding in normal B cells correlates well with preclinical ex vivo analysis of Btk protein in primary CLL cells where comparable Btk protein levels were found. This suggests that the AVL-292 dose range and schedule identified for complete Btk engagement in this healthy volunteer trial is likely to inform appropriate dose selection in the subsequent phase 1b oncology study, allowing more rapid identification of a safe and clinically effective dose. Disclosures: Evans: Avila Therapeutics: Employment, Equity Ownership. Tester:Avila Therapeutics: Employment, Equity Ownership. Aslanian:Avila Therapeutics: Employment, Equity Ownership. Chaturvedi:Avila Therapeutics: Employment, Equity Ownership. Mazdiyasni:Avila Therapeutics: Employment, Equity Ownership. Sheets:Avila Therapeutics: Employment, Equity Ownership. Nacht:Avila Therapeutics: Employment, Equity Ownership. Stiede:Avila Therapeutics: Employment, Equity Ownership. Witowski:Avila Therapeutics: Employment, Equity Ownership. Lounsbury:Avila Therapeutics: Employment, Equity Ownership. Petter:Avila Therapeutics: Employment, Equity Ownership. Singh:Avila Therapeutics: Employment, Equity Ownership. Westlin:Avila Therapeutics: Employment, Equity Ownership." @default.
• W2534353580 created "2016-10-28" @default.
• W2534353580 creator A5012574522 @default.
• W2534353580 creator A5016570475 @default.
• W2534353580 creator A5021057010 @default.
• W2534353580 creator A5022553023 @default.
• W2534353580 creator A5034625499 @default.
• W2534353580 creator A5043971328 @default.
• W2534353580 creator A5047897707 @default.
• W2534353580 creator A5048225313 @default.
• W2534353580 creator A5058755419 @default.
• W2534353580 creator A5059593640 @default.
• W2534353580 creator A5062122842 @default.
• W2534353580 creator A5068332039 @default.
• W2534353580 creator A5072335233 @default.
• W2534353580 creator A5074464534 @default.
• W2534353580 creator A5084316997 @default.
• W2534353580 creator A5086991181 @default.
• W2534353580 creator A5090303235 @default.
• W2534353580 date "2011-11-18" @default.
• W2534353580 modified "2023-09-27" @default.
• W2534353580 title "Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies," @default.
• W2534353580 doi "https://doi.org/10.1182/blood.v118.21.3485.3485" @default.
• W2534353580 hasPublicationYear "2011" @default.
• W2534353580 type Work @default.
• W2534353580 sameAs 2534353580 @default.
• W2534353580 citedByCount "12" @default.
• W2534353580 countsByYear W25343535802012 @default.
• W2534353580 countsByYear W25343535802013 @default.
• W2534353580 countsByYear W25343535802014 @default.
• W2534353580 countsByYear W25343535802017 @default.
• W2534353580 countsByYear W25343535802018 @default.
• W2534353580 countsByYear W25343535802019 @default.
• W2534353580 crossrefType "journal-article" @default.
• W2534353580 hasAuthorship W2534353580A5012574522 @default.
• W2534353580 hasAuthorship W2534353580A5016570475 @default.
• W2534353580 hasAuthorship W2534353580A5021057010 @default.
• W2534353580 hasAuthorship W2534353580A5022553023 @default.
• W2534353580 hasAuthorship W2534353580A5034625499 @default.
• W2534353580 hasAuthorship W2534353580A5043971328 @default.
• W2534353580 hasAuthorship W2534353580A5047897707 @default.
• W2534353580 hasAuthorship W2534353580A5048225313 @default.
• W2534353580 hasAuthorship W2534353580A5058755419 @default.
• W2534353580 hasAuthorship W2534353580A5059593640 @default.
• W2534353580 hasAuthorship W2534353580A5062122842 @default.
• W2534353580 hasAuthorship W2534353580A5068332039 @default.
• W2534353580 hasAuthorship W2534353580A5072335233 @default.
• W2534353580 hasAuthorship W2534353580A5074464534 @default.
• W2534353580 hasAuthorship W2534353580A5084316997 @default.
• W2534353580 hasAuthorship W2534353580A5086991181 @default.
• W2534353580 hasAuthorship W2534353580A5090303235 @default.
• W2534353580 hasConcept C126322002 @default.
• W2534353580 hasConcept C157695867 @default.
• W2534353580 hasConcept C159654299 @default.
• W2534353580 hasConcept C170493617 @default.
• W2534353580 hasConcept C203014093 @default.
• W2534353580 hasConcept C2777938653 @default.
• W2534353580 hasConcept C2778453870 @default.
• W2534353580 hasConcept C2778461978 @default.
• W2534353580 hasConcept C2779878957 @default.
• W2534353580 hasConcept C42362537 @default.
• W2534353580 hasConcept C43907098 @default.
• W2534353580 hasConcept C502942594 @default.
• W2534353580 hasConcept C71924100 @default.
• W2534353580 hasConcept C90059517 @default.
• W2534353580 hasConcept C98274493 @default.
• W2534353580 hasConceptScore W2534353580C126322002 @default.
• W2534353580 hasConceptScore W2534353580C157695867 @default.
• W2534353580 hasConceptScore W2534353580C159654299 @default.
• W2534353580 hasConceptScore W2534353580C170493617 @default.
• W2534353580 hasConceptScore W2534353580C203014093 @default.
• W2534353580 hasConceptScore W2534353580C2777938653 @default.
• W2534353580 hasConceptScore W2534353580C2778453870 @default.
• W2534353580 hasConceptScore W2534353580C2778461978 @default.
• W2534353580 hasConceptScore W2534353580C2779878957 @default.
• W2534353580 hasConceptScore W2534353580C42362537 @default.
• W2534353580 hasConceptScore W2534353580C43907098 @default.
• W2534353580 hasConceptScore W2534353580C502942594 @default.
• W2534353580 hasConceptScore W2534353580C71924100 @default.
• W2534353580 hasConceptScore W2534353580C90059517 @default.
• W2534353580 hasConceptScore W2534353580C98274493 @default.
• W2534353580 hasIssue "21" @default.
• W2534353580 hasLocation W25343535801 @default.
• W2534353580 hasOpenAccess W2534353580 @default.
• W2534353580 hasPrimaryLocation W25343535801 @default.
• W2534353580 hasRelatedWork W2154945466 @default.
• W2534353580 hasRelatedWork W2172629347 @default.
• W2534353580 hasRelatedWork W2529033697 @default.
• W2534353580 hasRelatedWork W2557815702 @default.
• W2534353580 hasRelatedWork W2767548364 @default.
• W2534353580 hasRelatedWork W2791299132 @default.
• W2534353580 hasRelatedWork W2802801749 @default.
• W2534353580 hasRelatedWork W2928972849 @default.
• W2534353580 hasRelatedWork W3010122964 @default.
• W2534353580 hasRelatedWork W3210817501 @default.
• W2534353580 hasVolume "118" @default.
• W2534353580 isParatext "false" @default.
• W2534353580 isRetracted "false" @default.

• next